Autoantibody and biopsy grading are associated with expression of ICAM-1, MMP-3, and TRAIL in salivary gland mononuclear cells of Chinese patients with Sjögren's Syndrome

Journal of Rheumatology

Volumn 36, Issue 5, 2009, Pages 989-996

  Chen, Wei Sheng ^a   Lin, Kuan Chia ^b   Chen, Chun Hsiung ^c   Liao, Hsien Tzung ^d   Wang, Hon Pin ^e   Li, Wing Yin ^a   Lee, Hui Ting ^a   Tsai, Chang Youh ^a   Chou, Chung Tei ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Antinuclear antibody; Matrix metalloproteinases; Minor salivary gland biopsy; Sj gren's Syndrome; Trail

Indexed keywords

AUTOANTIBODY; CD20 ANTIBODY; CHEMOKINE RECEPTOR CXCR3; INTERCELLULAR ADHESION MOLECULE 1; STROMELYSIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; TNFSF10 PROTEIN, HUMAN;

ADULT; ARTICLE; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; MINOR SALIVA GLAND; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SALIVARY GLAND BIOPSY; SIALOADENITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; AGED; ASIAN; BLOOD; ENZYME IMMUNOASSAY; EPITHELIUM CELL; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; EPITHELIAL CELLS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; INTERCELLULAR ADHESION MOLECULE-1; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; SALIVARY GLANDS, MINOR; SJOGREN'S SYNDROME; TAIWAN; TNF-RELATED APOPTOSIS-INDUCING LIGAND; YOUNG ADULT;

EID: 67449096837     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080733     Document Type: Article

References (53)

1. Talal N. Clinical and pathogenic aspects of Sjögren's syndrome. Semin Clin Immunol 1993;6:11-20.
2. Daniels TE, Fox PC. Salivary and oral components of Sjögren's syndrome. Rheum Dis Clin North Am 1992;18:571-89.
3. Xanthou G, Tapinos NI, Polihronis M, Nezis IP, Margaritis LH, Moutsopoulos HM. CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjögren's syndrome. Clin Exp Immunol 1999;118:154-63.
4. Daniels TE, Aufdemorte THB, Greenspan JS. Histopathology of Sjogren's syndrome. In: Tala LN, Moutsopoulos HM, Kassan SS, editors. Sjögren's syndrome. Clinical and immunological aspects. Berlin: Springer; 1987:258-65.
5. Kong L, Ogawa N, Nakabayashi T, et al. Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 1997;40:87-97.
6. Polihronis M, Tapinos NI, Theocharis SE, Economou A, Kittas C, Moutsopoulos HM. Modes of epithelial cell death and repair in Sjögren's syndrome. Clin Exp Immunol 1998;114:485-90.
7. Hansen A, Lipsky PE, Dorner T. Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol 2005;17:558-65.
8. van Woerkom JM, Geertzema JG, Nikkels PG, Kruize AA, Smeenk RJ, Vroom TM. Expression of Ro/SS-A and La/SS-B determined by immunohistochemistry in healthy, inflamed and autoimmune diseased human tissues: a generalized phenomenon. Clin Exp Rheumatol 2004;22:285-92.
9. Salomonsson S, Jonsson MV, Skarstein K, et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome. Arthritis Rheum 2003;48:3187-201.
10. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
11. Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 1998;161:2195-200.
12. Matsumura R, Umemiya K, Kagami M, et al. Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjögren's syndrome. Clin Exp Rheumatol 2002;20:791-8.
13. Chen CH, Lin KC, Yu DT, et al. Serum matrix metalloproteinase and tissue inhibitors of metalloproteinase in ankylosing spondylitis: MMP3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology 2006;45:414-20.
14. Yang C, Gu J, Rihl L, et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004;51:691-9.
15. Perez P, Kwon YJ, Alliende C, et al. Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios. Arthritis Rheum 2005;52:2751-60.
16. Wu AJ, Lafrenie RM, Park C, et al. Modulation of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by interferon-gamma in a human salivary gland cell line. J Cell Physiol 1997;171:117-24.
17. Dorner T, Hucko M, Mayet WJ, Trefzer U, Burmester GR, Hiepe F. Enhanced membrane expression of the 52 kDa Ro(SS-A) and La(SS-B) antigens by human keratinocytes induced by TNF alpha. Ann Rheum Dis 1995;54:904-9.
18. Turkcapar N, Sak SD, Saatci M, Duman M, Olmez U. Vasculitis and expression of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and E-selectin in salivary glands of patients with Sjögren's syndrome. J Rheumatol 2005;32:1063-70.
19. St. Clair EW, Angellilo JC, Singer KH. Expression of cell-adhesion molecules in the salivary gland microenvironment of Sjögren's syndrome. Arthritis Rheum 1992;35:62-6.
20. Edwards JC, Wilkinson LS, Speight P, Isenberg DA. Vascular cell adhesion molecule 1 and alpha 4 and beta 1 integrins in lymphocyte aggregates in Sjögren's syndrome and rheumatoid arthritis. Ann Rheum Dis 1993;52:806-11.
21. Mikulowska-Mennis A, Xu B, Berberian JM, Michie SA. Lymphocyte migration to inflamed lacrimal glands is mediated by vascular cell adhesion molecule-1/alpha(4)beta(1) integrin, peripheral node addressin/l-selectin, and lymphocyte function-associated antigen-1 adhesion pathways. Am J Pathol 2001;159:671-81.
22. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998;187:875-83.
23. Kim CH, Rott L, Kunkel EJ, et al. Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 2001;108:1331-9.
24. Shimizu S, Yoshinouchi T, Naniwa T, et al. Distribution of CXCR3- or CCR4-positive cells in interstitial pneumonia associated with primary Sjögren's syndrome. Virchows Arch 2004;445:477-84.
25. Wang XQ, Li XM, Li XP, et al. Immunopathology of salivary glands of patients with primary Sjögren's syndrome [Chinese]. Zhonghaa Yi Xue Za Zhi 2007;87:2505-7.
26. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
27. Cleland-Zamudio S, Demuth M, Trune DR. Pathology of labial salivary gland cellular aggregates in Sjögren's syndrome. Otolaryngol Head Neck Surg 1993;108:44-50.
28. Xu KP, Katagiri S, Takeuchi T, Tsubota K. Biopsy of labial salivary glands and lacrimal glands in the diagnosis of Sjögren's syndrome. J Rheumatol 1996;23:76-82.
29. Tak PP, van der Lubbe A, Cauli A, et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 1995;38:1457-65.
30. Chou CT, Yang JS, Lee MR. Apoptosis in rheumatoid arthritis - expression of Fas, Fas-L, p53 and Bcl-2 in rheumatoid synovial tissues. J Pathol 2001;193:110-6.
31. Kabasakal Y, Kitapcioglu G, Turk T, et al. The prevalence of Sjögren's syndrome in adult women. Scand J Rheumatol 2006;35:379-83.
32. Tomsic M, Rozman B. Sjogren's syndrome: a community-based study of prevalence and impact - comment on the article by Thomas et al. Rheumatology 1999;38:685-6.
33. Fox RI, Stern M, Michelson P. Update in Sjogren's syndrome. Curr Opin Rheumatol 2000;12:391-8.
34. Garcia-Carrasco M, Ramos-Casals M, Rosas J, et al. Primary Sjögren's syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine 2002;81:270-80.
35. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000;29:296-304.
36. Fossaluzza V, De Vita S. Clinical differences between ANA/anti-ENA positive or negative primary Sjögren's syndrome. Clin Rheumatol 1992;11:385-7.
37. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7.
38. Dafni UG, Tzioufas AG, Staikos P, Skopouli FN, Moutsopoulos HM. Prevalence of Sjogren's syndrome in a closed rural community. Ann Rheum Dis 1997;56:521-5.
39. Thomas E, Hay EM, Hajeer A, Silman AJ. Sjögren's syndrome: a community-based study of prevalence and impact. Br J Rheumatol 1998;37:1069-76.
40. Tomsic M, Logar D, Grmek M, Perkovic T, Kveder T. Prevalence of Sjögren's syndrome in Slovenia. Rheumatology 1999;38:164-70.
41. Yamamoto K. Pathogenesis of Sjögren's syndrome. Autoimmun Rev 2003;2:13-8.
42. Kessel A, Toubi E, Rozenbaum M, Zisman D, Sabo E, Rosner I. Sjögren's syndrome in the community: can serology replace salivary gland biopsy? Rheumatol Int 2006;26:337-9.
43. Haga HJ. Clinical and immunological factors associated with low lacrimal and salivary flow rate in patients with primary Sjögren's syndrome. J Rheumatol 2002;29:305-8.
44. Tsay CY, Wang CL, Chen TY, Huang CN, Hsu TC. SSA/RO antibodies in Chinese patients with systemic lupus erythematosus and Sjogren's syndrome. J Formos Med Assoc 1996;95:905-10.
45. Manganelli P, Fietta P. Apoptosis and Sjögren's syndrome. Semin Arthritis Rheum 2003;33:49-65.
46. Tsubota K, Fujita H, Tsuzaka K, Takeuchi T. Quantitative analysis of lacrimal gland function, apoptotic figures, Fas and Fas ligand expression of lacrimal glands in dry eye patients. Exp Eye Res 2003;76:233-40.
47. Masago R, Aiba-Masago S, Talal N, et al. Elevated proapoptotic Bax and caspase 3 activation in the NOD.scid model of Sjögren's syndrome. Arthritis Rheum 2001;44:693-702.
48. Jimenez F, Aiba-Masago S, Al Hashimi I, et al. Activated caspase 3 and cleaved poly (ADP-ribose) polymerase in salivary epithelium suggest a pathogenetic mechanism for Sjögren's syndrome. Rheumatology 2002;41:338-42.
49. Mariette X, Sibilia J, Roux S, Meignin V, Janin A. A new defensive mechanism to prevent apoptosis in salivary ductal cells from patients with Sjögren's syndrome: over-expression of p53 and p21. Rheumatology 2002;41:96-9.
50. Cuida M, Halse AK, Johannessen AC, Tynning T, Jonsson R. Indicators of salivary gland inflammation in primary Sjögren's syndrome. Eur J Oral Sci 1997;105:228-33.
51. Zhang NE, Shi CS, Yao QP, et al. Prevalence of primary Sjögren's syndrome in China. J Rheumatol 1995;22:659-61.
52. Loetscher P, Pellegrino A, Gong JH, et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 2001;276:2986-91.
53. Sfriso P, Oliviero F, Calabrese F, et al. Epithelial CXCR3-B regulates chemokines bioavailability in normal, but not in Sjögren's syndrome, salivary glands. J Immunol 2006;176:2581-9.